Acute Respiratory Distress Syndrome and COVID-19: A Literature Review

References

• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi:10.1001/jamainternmed.2020.0994
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hajage D, Demoule A, et al. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60–73. doi:10.1007/s00134-020-06294-x
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
   PubMed Web of Science ®Google Scholar
• Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi:10.1136/bmj.m1985
   PubMed Web of Science ®Google Scholar
• Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516. doi:10.1186/s13054-020-03240-7
   PubMed Web of Science ®Google Scholar
• Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818–824. doi:10.1164/ajrccm.149.3.7509706
   PubMed Web of Science ®Google Scholar
• Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38(10):1573–1582. doi:10.1007/s00134-012-2682-1
   PubMed Web of Science ®Google Scholar
• Riviello ED, Kiviri W, Twagirumugabe T, et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition. Am J Respir Crit Care Med. 2016;193(1):52–59. doi:10.1164/rccm.201503-0584OC
   PubMed Web of Science ®Google Scholar
• Tan W, Zhao X, Ma X, et al. A novel coronavirus genome identified in a cluster of pneumonia cases - Wuhan, China 2019–2020. China CDC Weekly. 2020;2(4):61–62. doi:10.46234/ccdcw2020.017
   PubMedGoogle Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–1581. doi:10.1001/jama.2020.5394
   PubMed Web of Science ®Google Scholar
• Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi:10.1038/s41591-020-0868-6
   PubMed Web of Science ®Google Scholar
• Xu W, Sun -N-N, Gao H-N, et al. Risk factors analysis of COVID-19 patients with ARDS and prediction based on machine learning. Sci Rep. 2021;11(1):2933. doi:10.1038/s41598-021-82492-x
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Marini J, Pesenti A, Quintel M, Mancebo J, Brochard L. The ”baby lung” became an adult. Intensive Care Med. 2016;42(5):663–673. doi:10.1007/s00134-015-4200-8
   PubMed Web of Science ®Google Scholar
• Lascarrou J-B. COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(21)00381-7
   PubMed Web of Science ®Google Scholar
• Tanner T, Offor OL, You JY, Hope AA, Gong MN, Chen J-T. Descriptive comparison between pre-COVID ARDS and COVID-19 related ARDS. TP48 TP048 COVID: ARDS CLINICAL STUDIES. American Thoracic Society. A2523; 2021.
   Google Scholar
• Li L, Li R, Wu Z, et al. Therapeutic strategies for critically ill patients with COVID-19. Ann Intensive Care. 2020;10(1):45. doi:10.1186/s13613-020-00661-z
   PubMed Web of Science ®Google Scholar
• Li X, Ma X. Acute respiratory failure in COVID-19: is it ”typical” ARDS? Crit Care. 2020;24(1):198. doi:10.1186/s13054-020-02911-9
   PubMed Web of Science ®Google Scholar
• Van Haren F, Page C, Laffey J, et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Critical Care. 2020;24:24. doi:10.1186/s13054-020-03148-2
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Pelosi P, Suter PM, Pedoto A, Vercesi P, Lissoni A. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med. 1998;158(1):3–11. doi:10.1164/ajrccm.158.1.9708031
   PubMed Web of Science ®Google Scholar
• Diamond M, Peniston Feliciano HL, Sanghavi D, Mahapatra S. Acute Respiratory Distress Syndrome. StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
   Google Scholar
• Moss M, Guidot DM, Steinberg KP, et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med. 2000;28(7):2187–2192. doi:10.1097/00003246-200007000-00001
   PubMed Web of Science ®Google Scholar
• Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA. 1996;275(1):50–54. doi:10.1001/jama.1996.03530250054027
   PubMed Web of Science ®Google Scholar
• Liu C, Li J. Role of genetic factors in the development of acute respiratory distress syndrome. J Transl Int Med. 2015;2(3):107–110. doi:10.4103/2224-4018.141831
   Google Scholar
• Meyer NJ, Christie JD. Genetic heterogeneity and risk of acute respiratory distress syndrome. Semin Respir Crit Care Med. 2013;34(4):459–474. doi:10.1055/s-0033-1351121
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267
   PubMed Web of Science ®Google Scholar
• Hussain M, Jabeen Q, Ahmad F, et al. COVID-19 and inhibitors of the renin–angiotensin–aldosterone system. Expert Rev Anti Infect Ther. 2021;19(7):815–816. doi:10.1080/14787210.2021.1851197
   PubMed Web of Science ®Google Scholar
• Zhu R-F, Gao Y-L, Robert S-H, Gao J-P, Yang S-G, Zhu C-T. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). J Transl Med. 2020;18(1):274. doi:10.1186/s12967-020-02442-5
   PubMed Web of Science ®Google Scholar
• Pfortmueller CA, Spinetti T, Urman RD, Luedi MM, Schefold JC. COVID-19-associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment – a narrative review. Best Pract Res Clin Anaesthesiol. 2021;35(3):351–368. doi:10.1016/j.bpa.2020.12.011
   PubMed Web of Science ®Google Scholar
• Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562–572. doi:10.1056/NEJMra1608077
   PubMed Web of Science ®Google Scholar
• Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–163. doi:10.1146/annurev-pathol-011110-130158
   PubMed Web of Science ®Google Scholar
• Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27(4):337–349. doi:10.1055/s-2006-948288
   PubMed Web of Science ®Google Scholar
• Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med. 1999;160(6):1843–1850. doi:10.1164/ajrccm.160.6.9901117
   PubMed Web of Science ®Google Scholar
• Fremont RD, Koyama T, Calfee CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma. 2010;68(5):1121–1127. doi:10.1097/TA.0b013e3181c40728
   PubMedGoogle Scholar
• Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010;137(2):288–296. doi:10.1378/chest.09-1484
   PubMed Web of Science ®Google Scholar
• Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med. 2014;42(3):691–700. doi:10.1097/01.ccm.0000435669.60811.24
   PubMed Web of Science ®Google Scholar
• Binnie A, Tsang JL, Dos Santos CC. Biomarkers in acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20(1):47–55. doi:10.1097/mcc.0000000000000048
   PubMed Web of Science ®Google Scholar
• Sweeney TE, Khatri P. Generalizable biomarkers in critical care: toward precision medicine. Crit Care Med. 2017;45(6):934–939. doi:10.1097/ccm.0000000000002402
   PubMed Web of Science ®Google Scholar
• Albertine KH, Soulier MF, Wang Z, et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol. 2002;161(5):1783–1796. doi:10.1016/s0002-9440(10)64455-0
   PubMed Web of Science ®Google Scholar
• Bos LD, Weda H, Wang Y, et al. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome. Eur Respir J. 2014;44(1):188–197. doi:10.1183/09031936.00005614
   PubMed Web of Science ®Google Scholar
• Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem. 2008;15(19):1911–1924. doi:10.2174/092986708785132942
   PubMed Web of Science ®Google Scholar
• Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. Arch Surg. 1985;120(5):536–540. doi:10.1001/archsurg.1985.01390290018003
   PubMed Web of Science ®Google Scholar
• Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317(25):1565–1570. doi:10.1056/NEJM198712173172504
   PubMed Web of Science ®Google Scholar
• Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138(1):62–68. doi:10.1164/ajrccm/138.1.62
   PubMed Web of Science ®Google Scholar
• Kido T, Muramatsu K, Asakawa T, et al. The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome: a retrospective and observational study using a nationwide administrative database in Japan. BMC Pulm Med. 2018;18(1):28. doi:10.1186/s12890-018-0597-5
   PubMedGoogle Scholar
• Annane D, Sébille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22–30. doi:10.1097/01.ccm.0000194723.78632.62
   PubMed Web of Science ®Google Scholar
• Liu L, Li J, Huang YZ, et al. [The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency]. Zhonghua Nei Ke Za Zhi. 2012;51(8):599–603. Chinese.
   PubMedGoogle Scholar
• Hirano Y, Madokoro S, Kondo Y, Okamoto K, Tanaka H. Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. J Intensive Care. 2020;8(1):91. doi:10.1186/s40560-020-00510-y
   PubMed Web of Science ®Google Scholar
• Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329. doi:10.1186/s13054-016-1511-2
   PubMed Web of Science ®Google Scholar
• Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–963. doi:10.1378/chest.06-2100
   PubMed Web of Science ®Google Scholar
• Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276. doi:10.1016/s2213-2600(19)30417-5
   PubMed Web of Science ®Google Scholar
• Festic E, Carr GE, Cartin-Ceba R, et al. Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*. Crit Care Med. 2017;45(5):798–805. doi:10.1097/ccm.0000000000002284
   PubMed Web of Science ®Google Scholar
• Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14(11):1149–1163. doi:10.1080/17476348.2020.1804365
   PubMed Web of Science ®Google Scholar
• Noreen S, Maqbool I, Madni A. Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021;894:173854. doi:10.1016/j.ejphar.2021.173854
   PubMed Web of Science ®Google Scholar
• Wu C, Hou D, Du C, et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. Crit Care. 2020;24(1):643. doi:10.1186/s13054-020-03340-4
   PubMed Web of Science ®Google Scholar
• Meduri G, Chinn A, Leeper K, et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Chest. 1994;105:1516–1527. doi:10.1378/chest.105.5.1516
   PubMed Web of Science ®Google Scholar
• Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–1684. doi:10.1056/NEJMoa051693
   PubMed Web of Science ®Google Scholar
• Pulakurthi YS, Pederson JM, Saravu K, et al. Corticosteroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2021;100(20):e25719. doi:10.1097/md.0000000000025719
   PubMed Web of Science ®Google Scholar
• Ma S, Xu C, Liu S, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Signal Transduction Targeted Therapy. 2021;6(1):83. doi:10.1038/s41392-021-00521-7
   PubMed Web of Science ®Google Scholar
• Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19. Int J Infect Dis. 2020;96:615–617. doi:10.1016/j.ijid.2020.05.115
   PubMed Web of Science ®Google Scholar
• Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1026–32. doi:10.1152/ajplung.00354.2004
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–987. doi:10.1038/nrd1901
   PubMed Web of Science ®Google Scholar
• O’Neal HRJ, Koyama T, Koehler EAS, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*. Crit Care Med. 2011;39(6):1343–1350. doi:10.1097/CCM.0b013e3182120992
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McKeown STW, O’Kane CM, et al. Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers. Am J Respir Crit Care Med. 2009;179(12):1107–1114. doi:10.1164/rccm.200810-1584OC
   PubMed Web of Science ®Google Scholar
• Mansur A, Steinau M, Popov AF, et al. Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study. BMC Med. 2015;13(1):128. doi:10.1186/s12916-015-0368-6
   PubMedGoogle Scholar
• Kruger P, Bailey M, Bellomo R, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med. 2013;187(7):743–750. doi:10.1164/rccm.201209-1718OC
   PubMed Web of Science ®Google Scholar
• Craig TR, Duffy MJ, Shyamsundar M, et al. A Randomized Clinical Trial of Hydroxymethylglutaryl– coenzyme A Reductase Inhibition for Acute Lung Injury (The HARP Study). Am J Respir Crit Care Med. 2011;183(5):620–626. doi:10.1164/rccm.201003-0423OC
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Z, Jiao W, Liu W, Liu F, Zhu X. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):196. doi:10.1186/s12890-019-0968-6
   PubMed Web of Science ®Google Scholar
• Leng YX, Yang SG, Song YH, Zhu X, Yao GQ. Ulinastatin for acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. World J Crit Care Med. 2014;3(1):34–41. doi:10.5492/wjccm.v3.i1.34
   PubMedGoogle Scholar
• Gao X-Q, Li Y-F, Jiang Z-L. Impact of statins on ALI/ARDS: a meta-analysis. Pulm Pharmacol Ther. 2016;39:85–91. doi:10.1016/j.pupt.2016.06.010
   PubMed Web of Science ®Google Scholar
• Xiong B, Wang C, Tan J, et al. Statins for the prevention and treatment of acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Respirology. 2016;21(6):1026–1033. doi:10.1111/resp.12820
   PubMed Web of Science ®Google Scholar
• Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370(23):2191–2200. doi:10.1056/NEJMoa1401520
   PubMed Web of Science ®Google Scholar
• McAuley DF, Laffey JG, O’Kane CM, et al. Simvastatin in the Acute Respiratory Distress Syndrome. N Eng J Med. 2014;371(18):1695–1703. doi:10.1056/NEJMoa1403285
   PubMed Web of Science ®Google Scholar
• Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J. 2020;6(4):258–259. doi:10.1093/ehjcvp/pvaa042
   Web of Science ®Google Scholar
• Masana L, Correig E, Rodríguez-Borjabad C, et al. EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED. Eur Heart J Cardiovasc Pharmacother. 2020. doi:10.1093/ehjcvp/pvaa128
   Web of Science ®Google Scholar
• Permana H, Huang I, Purwiga A, et al. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. Pharmacol Rep. 2021;73(3):769–780. doi:10.1007/s43440-021-00233-3
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): a systematic review, meta-analysis, and meta-regression. Nutrition, Metab Cardiovas Dis. 2021;31(6):1662–1670. doi:10.1016/j.numecd.2021.02.020
   PubMed Web of Science ®Google Scholar
• Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92(11):2283–2285. doi:10.1002/jmv.25948
   PubMed Web of Science ®Google Scholar
• Maes B, Bosteels C, De Leeuw E, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):468. doi:10.1186/s13063-020-04453-5
   PubMedGoogle Scholar
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/s0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Eng J Med. 2020;383(24):2333–2344. doi:10.1056/NEJMoa2028836
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux P-L, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: a Randomized Clinical Trial. JAMA Intern Med. 2021;181(1):32–40. doi:10.1001/jamainternmed.2020.6820
   PubMed Web of Science ®Google Scholar
• Ivan Hariyanto T, Kurniawan A. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection. J Med Virol. 2021;93(3):1832–1836. doi:10.1002/jmv.26698
   PubMed Web of Science ®Google Scholar
• Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32(11):2173–2182. doi:10.1097/01.ccm.0000145229.59014.6c
   PubMed Web of Science ®Google Scholar
• Yanik GA, Grupp SA, Pulsipher MA, et al. TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children’s Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015;21(1):67–73. doi:10.1016/j.bbmt.2014.09.019
   PubMed Web of Science ®Google Scholar
• Yanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008;112(8):3073–3081. doi:10.1182/blood-2008-03-143412
   PubMed Web of Science ®Google Scholar
• Stallmach A, Kortgen A, Gonnert F, Coldewey SM, Reuken P, Bauer M. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series. Critical Care. 2020;24(1):444. doi:10.1186/s13054-020-03158-0
   PubMed Web of Science ®Google Scholar
• Correger E, Marcos J, Laguens G, Stringa P, Cardinal-Fernández P, Blanch L. Tratamento prévio com adalimumabe reduz lesão pulmonar induzida por ventilação mecânica em um modelo experimental. Revista Brasileira de Terapia Intensiva. 2020;32:58–65. doi:10.5935/0103-507x.20200010
   PubMedGoogle Scholar
• Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19(2):1520–1529. doi:10.1164/rccm.201310-1892OC
   Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Eng J Med. 2020;384(9):795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled Phase 3 trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(21)00331-3
   Google Scholar
• Proudfoot AG, O’Kane CM, Bayliffe A, et al. A Novel TNFR1-Targeting Domain Antibody Attenuates Pulmonary Inflammation In A Human Model Of Lung Injury, Via Actions On The Lung Micro-Vascular Endothelium. A47 CRITICAL ILLNESS: NOVEL MOLECULES and MODELS. American Thoracic Society. A6589; 2014.
   Google Scholar
• Watanabe M, Boyer JL, Crystal RG. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther. 2009;20(6):598–610. doi:10.1089/hum.2008.169
   PubMed Web of Science ®Google Scholar
• Gainnier M, Roch A, Forel JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2004;32(1):113–119. doi:10.1097/01.Ccm.0000104114.72614.Bc
   PubMed Web of Science ®Google Scholar
• Forel JM, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006;34(11):2749–2757. doi:10.1097/01.Ccm.0000239435.87433.0d
   PubMed Web of Science ®Google Scholar
• Papazian L, Forel J-M, Gacouin A, et al. Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. N Eng J Med. 2010;363(12):1107–1116. doi:10.1056/NEJMoa1005372
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Alshahrani M, Jaeschke R, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Critical Care. 2013;17(2):R43. doi:10.1186/cc12557
   PubMed Web of Science ®Google Scholar
• Courcelle R, Gaudry S, Serck N, Blonz G, Lascarrou JB, Grimaldi D. Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study. Critical Care. 2020;24:24. doi:10.1186/s13054-020-03164-2
   PubMed Web of Science ®Google Scholar
• Fukimbara S, Niibe K, Yamamoto M, Yamaguchi T. Adjustment for propensity score in nonrandomized clinical studies: comparison of sivelestat versus conventional therapy for acute respiratory distress syndrome. Therapeutic Innovatio Regulatory Sci. 2017;5(1):89–99. doi:10.1177/2168479016659103
   Google Scholar
• Endo S, Sato N, Yaegashi Y, et al. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. Res Commun Mol Pathol Pharmacol. 2006;119(1–6):53–65.
   PubMedGoogle Scholar
• Sahchbnasagh A, Saghafi F, Safdari M, et al. Neutrophil Elastase Inhibitor (Sivelestat), may be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in COVID-19. Authorea. 2020;4:548.
   Google Scholar
• Stockley R, DeSoyza A, Gunawardena K, et al. Phase 2 study of a neutrophil elastase inhibitor (AZD9668} in patients with bronchiectasis. Respir Med. 2013;107(4):524–533. doi:10.1016/j.rmed.2012.12.009
   PubMed Web of Science ®Google Scholar
• Edwards A, Taggart C, Elborn J, Calfee CS, Matthay MA, O’Kane C. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med. 2014;189(12):1520–1529. doi:10.1164/rccm.201310-1892OC
   PubMed Web of Science ®Google Scholar
• Dixon B, Schultz MJ, Smith R, Fink JB, Santamria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Critical Care. 2010;14(5):180. doi:10.1186/cc9286
   PubMed Web of Science ®Google Scholar
• Chen W, Janz DR, Bastarache JA, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med. 2015;43(4):801–807. doi:10.1097/CCM.0000000000000789
   PubMed Web of Science ®Google Scholar
• Kor DJ, Carter RE, Park PK, et al. Lung injury prevention with aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: the LIPS-A Randomized Clinical Trial. JAMA. 2016;315(22):2406. doi:10.1001/jama.2016.6330
   PubMed Web of Science ®Google Scholar
• Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178(6):618–623. doi:10.1164/rccm.200803-419OC
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McAuley DF, Ingram RJ, et al. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am j Respir Critical Care Med. 2014;189(12):1520–1529.
   PubMed Web of Science ®Google Scholar
• McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017;5(6):484–491. doi:10.1016/S2213-2600(17)30171-6
   PubMed Web of Science ®Google Scholar
• Paine R, Standiford TJ, Dechert RE. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med. 2012;40(1):90–97. doi:10.1097/CCM.0b013e31822d7bf0
   PubMed Web of Science ®Google Scholar
• Fowler AA, Truwit JD, Hite RD. Effect of vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: the CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322(13):1261–1270. doi:10.1001/jama.2019.11825
   PubMed Web of Science ®Google Scholar
• Grant WB. Vitamin D supplementation of mother and infant could reduce risk of sepsis in premature infants. Early Hum Dev. 2010;86(2):133. doi:10.1016/j.earlhumdev.2010.02.003
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Intan D, Hananto JE, Harapan H, Kurniawan A. Vitamin D supplementation and Covid-19 outcomes: a systematic review, meta-analysis and meta-regression. Rev Med Virol. 2015:1;e2269. doi:10.1002/rmv.2269
   Google Scholar
• Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105(1):190–194. doi:10.1378/chest.105.1.190
   PubMed Web of Science ®Google Scholar
• Paterson RL, Galley HF, Webster NR. The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med. 2003;31(11):2574–2578. doi:10.1097/01.Ccm.0000089945.69588.18
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Lugito NPH, Yanto TA, Siregar JI, Kurniawan A. Insulin therapy and outcome from coronavirus disease 2019 (COVID-19): a Systematic Review, Meta-Analysis, and Meta-Regression. Endocr Metab Immune Disord Drug Targets. 2021;5:55. doi:10.2174/1871530321666210709164925
   Google Scholar
• Yang Y, Cai Z, Zhang J. Insulin Treatment May Increase Adverse Outcomes in Patients With COVID-19 and Diabetes: a Systematic Review and Meta-Analysis. Original Research. Front Endocrinol (Lausanne). 2021;12:894. doi:10.3389/fendo.2021.696087
   Web of Science ®Google Scholar
• Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies. Rev Med Virol. 2015:1;e2265. doi:10.1002/rmv.2265
   Google Scholar
• Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021;48(6):823–830. doi:10.1111/1440-1681.13488
   PubMed Web of Science ®Google Scholar
• Drago BB, Kimura D, Rovnaghi CR, et al. Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome. Pediatr Crit Care Med. 2015;16(3):e74–81. doi:10.1097/PCC.0000000000000349
   PubMedGoogle Scholar
• Proudfoot A, Bayliffe A, O’Kane CM, et al. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax. 2018;73(8):723–730. doi:10.1136/thoraxjnl-2017-210305
   PubMed Web of Science ®Google Scholar
• Vincent JL, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med. 2009;37(6):1874–1880. doi:10.1097/CCM.0b013e31819fff2c
   PubMed Web of Science ®Google Scholar
• Cornet AD, Groeneveld ABJ, Hofstra JJ, et al. Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial. PLoS One. 2014;9(3):e90983–e90983. doi:10.1371/journal.pone.0090983
   PubMed Web of Science ®Google Scholar
• Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997–2008. doi:10.1056/NEJMoa1901686
   PubMed Web of Science ®Google Scholar
• Aikawa N, Ishizaka A, Hirasawa H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011;24(5):549–554. doi:10.1016/j.pupt.2011.03.001
   PubMed Web of Science ®Google Scholar
• Kido T, Muramatsu K, Yatera K, et al. Efficacy of early sivelestat administration on acute lung injury and acute respiratory distress syndrome. Respirology. 2017;22(4):708–713. doi:10.1111/resp.12969
   PubMed Web of Science ®Google Scholar
• Fukimbara S, Niibe K, Yamamoto M, Yamaguchi T. Adjustment for propensity score in nonrandomized clinical studies: comparison of sivelestat versus conventional therapy for acute lung injury in acute respiratory distress syndrome. Ther Innov Regul Sci. 2017;51(1):89–99. doi:10.1177/2168479016659103
   PubMed Web of Science ®Google Scholar
• Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112(1):164–172. doi:10.1378/chest.112.1.164
   PubMed Web of Science ®Google Scholar
• Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1997;12(4):177–182. doi:10.1016/s0883-9441(97)90029-0
   PubMed Web of Science ®Google Scholar
• Morris PE, Papadakos P, Russell JA, et al. A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome. Crit Care Med. 2008;36(3):782–788. doi:10.1097/ccm.0b013e318164e7e4
   PubMed Web of Science ®Google Scholar
• Fowler AA 3rd, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the citris-ali randomized clinical trial. JAMA. 2019;322(13):1261–1270. doi:10.1001/jama.2019.11825
   PubMed Web of Science ®Google Scholar
• ARDS Network Authors For The ARDS Network T. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA. 2000;283(15):1995–2002. doi:10.1001/jama.283.15.1995
   PubMed Web of Science ®Google Scholar
• McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017;5(6):484–491. doi:10.1016/s2213-2600(17)30171-6
   PubMed Web of Science ®Google Scholar
• Paine R 3rd, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med. 2012;40(1):90–97. doi:10.1097/CCM.0b013e31822d7bf0
   PubMed Web of Science ®Google Scholar
• Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Eng J Med. 1996;334(22):1417–1422. doi:10.1056/NEJM199605303342201
   PubMed Web of Science ®Google Scholar
• Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351(9):884–892. doi:10.1056/NEJMoa033181
   PubMed Web of Science ®Google Scholar
• Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999;27(8):1478–1485. doi:10.1097/00003246-199908000-00013
   PubMed Web of Science ®Google Scholar
• Network ACT. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002;30(1):1–6. doi:10.1097/00003246-200201000-00001.
   PubMed Web of Science ®Google Scholar
• Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet. 2012;379(9812):229–235. doi:10.1016/S0140-6736(11)61623-1
   PubMed Web of Science ®Google Scholar
• Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306(14):1574–1581. doi:10.1001/jama.2011.1435
   PubMed Web of Science ®Google Scholar
• Willson DF, Truwit JD, Conaway MR, Traul CS, Egan EE. The adult calfactant in acute respiratory distress syndrome trial. Chest. 2015;148(2):356–364. doi:10.1378/chest.14-1139
   PubMed Web of Science ®Google Scholar
• Limaye AP, Stapleton RD, Peng L, et al. Effect of ganciclovir on IL-6 levels among Cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA. 2017;318(8):731–740. doi:10.1001/jama.2017.10569
   PubMed Web of Science ®Google Scholar